[Trastuzumab in the breast cancer treatment: efficacy and resistance mechanisms].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Author(s): Grell P;Grell P; Svoboda M; Simícková M; Fabian P; Vyzula R
  • Source:
    Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti [Klin Onkol] 2009; Vol. 22 (2), pp. 45-51.
  • Publication Type:
    English Abstract; Journal Article; Review
  • Language:
    Slovak
  • Additional Information
    • Transliterated Title:
      Trastuzumab v liecbe karcinómu prsníka: mechanizmy úcinku a rezistencie.
    • Source:
      Publisher: Ceská lékarská spolecnost Country of Publication: Czech Republic NLM ID: 9425213 Publication Model: Print Cited Medium: Print ISSN: 0862-495X (Print) Linking ISSN: 0862495X NLM ISO Abbreviation: Klin Onkol Subsets: MEDLINE
    • Publication Information:
      Original Publication: Brno : Ceská lékarská spolecnost,
    • Subject Terms:
      Drug Resistance, Neoplasm*; Antibodies, Monoclonal/*therapeutic use ; Antineoplastic Agents/*therapeutic use ; Breast Neoplasms/*drug therapy; Antibodies, Monoclonal, Humanized ; Breast Neoplasms/genetics ; Female ; Genes, erbB-2 ; Humans ; Trastuzumab
    • Abstract:
      Trastuzumab, a humanized monoclonal antibody against the HER-2 receptor, was the first targeted therapy for HER-2 positive breast cancer. The treatment of HER-2 positive breast cancer in monotherapy, but mainly in combination with cytostatics trastuzumab, showed significant efficacy and increased the time to progression/relapse and overall survival. On the other hand, despite it being administered to only a selected patient population, the response rate varies in range and duration due to the primary or acquired tumor resistance to trastuzumab. Several mechanisms contributing to the drug resistance are presumed and overcoming strategies are in development. In connection with the drug resistance there are the mechanisms of trastuzumab's action on tumor cells and the search for feasible biomarkers in order to predict the response of trastuzumab-based targeted therapies. Furthermore, we present here the actual possibilities to overcome primary or acquired trastuzumab resistance.
    • Number of References:
      57
    • Accession Number:
      0 (Antibodies, Monoclonal)
      0 (Antibodies, Monoclonal, Humanized)
      0 (Antineoplastic Agents)
      P188ANX8CK (Trastuzumab)
    • Publication Date:
      Date Created: 20090616 Date Completed: 20090804 Latest Revision: 20151119
    • Publication Date:
      20240513
    • Accession Number:
      19522373